Search tips
Search criteria 


Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
J Clin Invest. 2010 July 1; 120(7): 2590–2599.
Published online 2010 June 14. doi:  10.1172/JCI42051
PMCID: PMC2898603

A molecular switch controls interspecies prion disease transmission in mice


Transmissible spongiform encephalopathies are lethal neurodegenerative disorders that present with aggregated forms of the cellular prion protein (PrPC), which are known as PrPSc. Prions from different species vary considerably in their transmissibility to xenogeneic hosts. The variable transmission barriers depend on sequence differences between incoming PrPSc and host PrPC and additionally, on strain-dependent conformational properties of PrPSc. The β22 loop region within PrPC varies substantially between species, with its structure being influenced by the residue types in the 2 amino acid sequence positions 170 (most commonly S or N) and 174 (N or T). In this study, we inoculated prions from 5 different species into transgenic mice expressing either disordered-loop or rigid-loop PrPC variants. Similar β22 loop structures correlated with efficient transmission, whereas dissimilar loops correlated with strong transmission barriers. We then classified literature data on cross-species transmission according to the 170S/N polymorphism. Transmission barriers were generally low between species with the same amino acid residue in position 170 and high between those with different residues. These findings point to a triggering role of the local β22 loop structure for prion transmissibility between different species.


Transmissible spongiform encephalopathies (TSEs) are lethal neurodegenerative disorders that include kuru and Creutzfeldt-Jakob disease (CJD) in humans, bovine spongiform encephalopathy (BSE) in cows, scrapie in sheep and goats, and chronic wasting disease (CWD) in cervids (1). A crucial component of the infectious agent is PrPSc, a highly aggregated, β-sheet–rich isoform of the cellular prion protein (PrPC) (2, 3).

Prion diseases can occur as distinct strains within species expressing identical PrP amino acid sequences (4). Prion strains have originally been defined by transmission to mice, in which they show different incubation periods (ips) and variable brain regions targeted (57). Evidence is accumulating that distinct strains represent different PrPSc conformations (811).

There is evidence that interspecies prion transmission occurs in nature, and it has thus become an important food safety issue. Dietary exposure to beef contaminated with the BSE agent is believed to have caused nearly 200 cases of variant CJD (vCJD) in humans (1215) as well as spongiform encephalopathies in domestic cats and British zoo animals (1619). Prion transmission across species barriers has been replicated experimentally and typically leads to incomplete attack rates and to prolonged, highly variable ips (20). Understanding the factors that dictate species barriers is crucial for assessing the risk for human prion disease, particularly as new prion strains may arise in food animals (2124).

Experimental studies of species and strain barriers in vitro and in vivo indicate that certain amino acid positions have an outstandingly strong influence on prion transmission among species with heterologous prion protein (Prnp) sequences (4, 2532). For example, hamsters resist infection with mouse prions, although the hamster and mouse Prnp sequences differ at only 9 residues (3032). Similarly, knock-in mice that only differ from WT mice at codon 101 of the Prnp allele show highly divergent susceptibility to sheep scrapie, BSE, and CJD (33, 34).

Susceptibility to natural prion infections may also be influenced by Prnp polymorphisms. Humans are polymorphic at PRNP codon 129 (methionine/valine). While approximately 38% of Europeans are 129MM homozygous, 100% of the confirmed vCJD cases have occurred in 129MM patients (35), indicating selective susceptibility of this allotype to BSE prions. Since the efficiency of TSE transmission into a new species further appears to vary depending on the prion strain (33, 36, 37), the increased susceptibility of humans carrying the 129MM alleles may not be maintained with future BSE strains.

Although the amino acid sequence of PrPC is overall highly conserved among mammals, the β2-α2 loop encompassing residues 165–175 is a site of outstandingly high sequence diversity (38). The 3-dimensional structure of PrPC immediately led to the identification of this loop as a key part of the surface epitope that might influence species barriers (39, 40), and this hypothesis also received support from molecular dynamics simulations (41). Mature PrPC contains a flexibly unstructured N-terminal 100-residue “tail” and a globular C-terminal domain of similar size, which contains 3 α-helices and a short antiparallel β-sheet (40, 42, 43). The β22 loop is structurally polymorphic in that amino acid sequences that contain 170S and 174N form a poorly defined loop in the NMR solution structures at 20°C (4447), whereas sequences that contain 170N, or 170N and 174T (numbering according to ref. 48) have a well-defined loop (4951). Here, we used transgenic mice expressing prion proteins that differ in discrete sequence positions of the β22 loop to further investigate the effect of the loop structure on interspecies prion transmission. We found that sequence variations affecting only the β22 loop conformation can significantly impact cross-species susceptibility to a broad array of prion diseases.


To determine the impact of the loop sequence on interspecies transmission, we used 2 lines of transgenic mice expressing PrPC variants that differ by 2 amino acid residues. tga20 mice overexpressed WT mouse PrP, whereas tg1020 mice overexpressed a “rigid loop” (RL) variant of PrP with S170N and N174T substitutions (Figure (Figure1A).1A). In both mouse lines, the transgene was expressed in the context of a “half-genomic” prion minigene construct. Expression levels were approximately 6- and 3-fold higher in tga20 and tg1020 mice, respectively, than those for endogenous PrPC (52, 53).

Figure 1
Amino acid sequence and 3-dimensional structure comparisons for WT mouse PrPC (Prnp a), mouse RL-PrPC, and for WT-PrPC of 4 additional mammalian species.

Mice were inoculated with prions derived from 5 species (Figure (Figure1A),1A), for which PrPC 3-dimensional structures have been fully characterized by solution NMR spectroscopy: sheep, cattle, cervid, hamster, and mouse (Figure (Figure1B).1B). The overall structure of the C-terminal globular domain is nearly identical among these 5 species (Figure (Figure1B),1B), yet they differ in the local conformations of the β22 loop (Figure (Figure1C)1C) encompassing residues 165–175 (40, 4447, 50, 51).

Inoculation with mouse scrapie strains.

All prion strains used for the inoculations were proteinase K (PK) resistant. Therefore, the criterion used for determining transmission to tg1020 and tga20 mice was the presence of PK-resistant PrPSc in the brain of the recipients as well as development of a rapidly progressive neurologic disease with widespread spongiosis. To assess the susceptibility of WT-PrP and RL-PrP mice to mouse-adapted scrapie, we inoculated tga20 and tg1020 mice intracerebrally with 104 LD50 of Rocky Mountain Laboratory (scrapie strain passage 5, referred to herein as RML5) prions (Figure (Figure2A).2A). tga20 mice developed terminal prion disease in 74 ± 6 days, whereas tg1020 mice developed disease after a much longer and more variable ip (323 ± 92 days; unpaired, 2-tailed Student’s t test, P = 0.002; Figure Figure2B2B and Table Table1).1). The prion-containing brain homogenate recovered from the latter mice was termed RL-RML1 (RL-passaged RML, first passage). WT mice developed scrapie in 170 ± 12 days after inoculation with 103 log LD50 of the same inoculum (Figure (Figure2B),2B), indicating that RL-PrP mice developed disease with a 47% increase in the ip compared with the WT mice.

Figure 2
The RL induces a species barrier for RML infection.
Table 1
Passage of mouse, deer, hamster, cattle, and sheep TSEs into mice expressing mouse PrPC or RL-PrPC

RML-PrPSc aggregates in brain displayed similar morphologies in tga20 and tg1020 mice, consisting of widespread deposits visible by immunohistochemistry (Figure (Figure2C).2C). Elderly uninoculated tg1020 mice developed a spontaneous transmissible prion disease, with focal cerebral PrP plaques (53), yet the morphology of these spontaneous deposits was profoundly different from the widespread diffuse deposits developing in inoculated mice. Also, N-terminally cleaved PrP never acquired PK resistance of all 3 glycoforms in spontaneously sick tg1020 mice. Therefore, the PK-resistant PrPSc detected in tg1020 and tga20 mice indicates that transmission of RML prions had occurred in both strains of host mice.

Inoculation of RL-RML1 homogenate into a further generation of tg1020 mice resulted in a shortening of the ip and a reduction of variability by nearly 50%, to 171 ± 11 days (Figure (Figure2,2, A and B, and Table Table1).1). Hence, the substitutions of residues 170 and 174 had created a species barrier for RML prions, which was overcome by serial passaging. Conversely, back passage of the RL-RML1 inoculum into tga20 mice led to a more than 50% increase in the ip and to a 5-fold increase in variability (186 ± 33 days; Figure Figure2B2B and Table Table1).1). The latter results point to a species barrier erected by the WT-Prnp sequence against RL-PrP prions. In conclusion, mouse prions could be adapted to hosts expressing either WT or RL Prnp; both resulting inocula were readily propagated in hosts expressing the same Prnp variant but were much less amenable to propagation in hosts expressing the other variant. This fulfills the definition of a species barrier.

RL-RML1 PrPSc aggregates were sparsely distributed in tga20 mice but were widespread in tg1020 mice, as shown by immunohistochemistry and histoblotting (Figure (Figure2D).2D). Neither RML nor RL-RML1 tissue deposits were stained by Congo red (Supplemental Figure 1; supplemental material available online with this article; doi: 10.1172/JCI42051DS1). We stained brain sections with the fluorescent amyloidotropic dye, polythiophene acetic acid (PTAA) (54). PTAA stains PrPSc deposits and emits distinct fluorescence spectra that report on the supramolecular arrangement of protein aggregates.

All RML-infected tg1020 brains, but none of the tga20 brains, contained PTAA+ plaques (Figure (Figure2C).2C). We compared PTAA emissions by plotting the fluorescence intensity ratio at 531 and 642 nm (R531/642) against the ratio between the intensity at 531 nm and at the emission maximum (R531/Emax). The resulting values are independent of absolute fluorescence intensity and can discriminate among multiple prion strains (55, 56). PTAA emission characteristics were highly variable among animals and sometimes even within individual animals, suggesting highly polymorphic PrPSc conformations in the first passage of RML (Figure (Figure2E).2E). However, none of the tga20 and tg1020 mice inoculated with RL-RML1 prions had PTAA+ plaques. This finding suggests that the supramolecular arrangements of PrPSc had changed drastically upon passage.

We then compared brain homogenates of tga20 and tg1020 mice inoculated with RL-RML1 by PK digestion followed by Western blotting. The concentration of PrPSc was relatively homogenous in tg1020 mice but highly variable in tga20 mice (Figure (Figure2F).2F). We concluded that the S170N and N174T substitutions created a species barrier to RML prions, which was eventually overcome in the RL mice through multiple passages.

Inoculation with CWD infectious brain homogenate.

We then inoculated tg1020 and tga20 mice with CWD prions from a terminal, naturally infected mule deer. WT mice are resistant to infection with CWD prions (57, 58), whereas overexpression of WT Prnp renders tga20 mice susceptible to CWD — albeit after long ips (59). The mature PrPC sequences of mice and mule deer differ at 23 residues, but the 165–175 loop sequence in tg1020 mice is identical to that of deer and elk (Figure (Figure1A). 1A).

CWD infection led to accelerated disease in tg1020 mice compared with tga20 mice (279 ± 48 days and 543 ± 72 days, respectively; Figure Figure3A3A and Table Table1)1) (unpaired, 2-tailed Student’s t test, P = 0.001). We detected abundant fine and clumped aggregates in hippocampus and cerebral cortex by using immunohistochemistry for PrP in tg1020 mice. The PTAA emission spectra were similar for all histologically visible aggregates in the first CWD passage, with little variability within and between tg1020 animals.

Figure 3
Mule deer CWD infection of tga20 and tg1020 mice.

Surprisingly, the second passage of RL-CWD in tg1020 mice resulted in a slight lengthening of the ip (Figure (Figure3A3A and Table Table1).1). Using immunohistochemistry for PrP and PTAA emission spectra, 2 conspicuously differing PrPSc aggregate morphologies emerged: (a) a noncongophilic type, with a low R531/642 similar to the first passage, and (b) a rare, 50- to 100-μm dense congophilic type, with a high R531/642 (Figure (Figure3B).3B). The R531/642, which depends on fluorescence resonance transfer between PTAA molecules, indicated that the LCP chains were tightly packed in the noncongophilic aggregates and loosely packed in the congophilic aggregates (Figure (Figure3C).3C). Maybe the conformational variants were interfering with the conversion of each other, thereby resulting in an unexpectedly long ip.

We then investigated the biochemical profile of CWD-induced PrPSc in tg1020 brain homogenates using PK digestion and PrP immunoblotting. The first passage of CWD in tg1020 mice yielded barely detectable PK-resistant PrPSc. By the second passage, PK-resistant PrP showed the typical shift in electrophoretic mobility, suggesting that a PK-resistant form had become more abundant (Figure (Figure3D). 3D).

We then assessed the effect of the PrPSc primary amino acid sequence on the strain properties by comparing a mouse-adapted CWD (M-CWD) strain with mule deer CWD in tg1020 mice. There was no significant difference in the ips: M-CWD–infected tg1020 mice (Figure (Figure3E)3E) and mule deer CWD–infected tg1020 mice (Figure (Figure3A)3A) had ips of 252 ± 51 days and 279 ± 48 days, respectively (Student’s t test, P = 0.45).

PrP aggregates in the M-CWD–inoculated tg1020 brains histologically appeared large and congophilic (Figure (Figure3F),3F), similar to the rare congophilic plaques seen in the RL-CWD–infected tg1020 mice and the M-CWD–infected tga20 mice (Figure (Figure3,3, B and F). The LCP emission spectra R531/642 and R531/Emax were also similar (Figure (Figure3G),3G), with values that are indicative of loosely packed PTAA chains.

The above data indicate that after primary deer CWD inoculation, RL-PrP may give rise to morphologically small, noncongophilic aggregates, leading to tight packing of PTAA, or large, congophilic plaques, leading to looser packing of PTAA. In contrast, the M-CWD strain gave rise to a single morphology in both tga20 and tg1020 mice, which appeared similar to the large congophilic plaques described above.

Inoculation of hamster scrapie into RL-PrP and WT-PrP mice.

Mice were initially believed to be completely resistant to infection with particular strains of hamster prions (60), but an extensive series of experiments revealed that mice can replicate hamster prions subclinically (32). The hamster PrPC β22 loop sequence is homologous with the RL-PrP sequence at position 170N and with the WT mouse sequence at 174N. To determine whether either WT-PrP or RL-PrP, or both, could support hamster prion replication, we inoculated tga20 and tg1020 mice with the Sc237 strain of hamster prions. The ips were consistently more than 400 days for all mice, but the attack rate varied markedly. Whereas 6 out of 6 tg1020 mice showed N-terminally cleaved, PK-resistant PrPSc accumulation in histoblot and Western blot assays (Figure (Figure4,4, A and B), versus a background of 0 out of 13 uninoculated tg1020 mice (Supplemental Figure 2), only 1 out of 4 tga20 mice had any detectable PrPSc, even following concentration of PrPSc by sodium phosphotungstic acid precipitation (Figure (Figure4B).4B). tg1020 mice, but not tga20 mice, showed conspicuous spongiform encephalopathy, which was particularly evident in the cerebral cortex (Figure (Figure4C).4C). PrPSc aggregates were finely granular and diffusely distributed (Figure (Figure4A).4A). The Congo red, PTAA, and polythiophene methyl imidazole (PTMI) stains were negative (Supplemental Figures 1 and 3), precluding emission spectra comparisons with RL-RML or RL-CWD. We concluded that hamster scrapie could be consistently transmitted to tg1020 but not tga20 mice. The long ip suggests either inefficient transmission or generation of PrPSc aggregates with low toxicity.

Figure 4
Hamster scrapie infects tg1020 mice.

Inoculation with BSE and sheep scrapie.

We inoculated tg1020 and tga20 mice with BSE and sheep scrapie isolates (Swiss BSE and Colorado sheep scrapie from single animals). Cattle, sheep, and mouse PrP protein sequences are identical at the β22 loop, and both BSE and sheep scrapie isolates can infect tga20 mice, as previously reported (56). After inoculation with BSE or sheep scrapie, aged tg1020 mice (>300 days old) developed weight loss and mild paraparesis as well as rare RL-PrP plaques in the hippocampus. However, in the tg1020 mice there was no evidence for BSE or sheep scrapie transmission by any method. PrP histoblots and Western blots were consistently negative for PK-resistant PrPSc (Supplemental Figures 2 and 4).

In vitro cross-species PrPSc amplification using protein misfolding cyclic amplification.

To assess whether the transmission barrier induced by the S170N and N174T substitutions could be reproduced in vitro, we performed protein misfolding cyclic amplification (PMCA) experiments, using the tg1020 and tga20 brain as a substrate. We seeded the PMCA reaction with RML mouse prions, 263K hamster scrapie, deer CWD, and Colorado sheep scrapie. Six separate samples of tg1020 and tga20 brain were seeded with each prion strain and amplified for 5 rounds (Table (Table22 and Supplemental Figure 5). We found that by the fifth round, tg1020 brain homogenates yielded PK-resistant PrP in 100% of samples seeded with hamster scrapie and 83% of samples seeded with CWD, compared with only 17% and 50% of tga20 brain homogenates seeded with hamster scrapie and CWD, respectively. tg1020 and tga20 brain homogenate led to PK-resistant PrP in all samples seeded with RML but in no samples seeded with sheep scrapie. Therefore, the PMCA experiments largely reproduced our in vivo findings; the main difference occurred with sheep scrapie, in which PK-resistant PrPSc was not detected in any of the tga20 and tg1020 samples. Although we have shown that the tga20 mice and tg1020 mice were both susceptible to RML infection, the difference in the ip was not revealed by differences in seeding ability using PMCA.

Table 2
Serial automated PMCA using tg1020 brain homogenate as the substrate


170 and 174 are positions that can modulate prion transmission.

The S170N and N174T substitutions in the β22 loop of PrPC erected a complete barrier to TSEs derived from 2 different host species, cattle and sheep (Table (Table3).3). Conversely, the very strong barrier of mice against hamster prions was completely ablated, as hamster prions infected all mice expressing RL-PrPC (Table (Table3).3). The potent impact on species barriers caused by 2 amino acid substitutions indicates that prion species barriers may be profoundly altered in humans or animals expressing polymorphisms or mutant PrP molecules. Thus, human or animal TSEs may be replicated by mutant molecules, even when otherwise strong species barriers are known to exist.

Table 3
Interspecies transmission of TSEs in tga20 and tg1020 mice, as determined by PK-resistant PrPSc in brain

TSE infection in the tg1020 mice.

We have previously reported that tg1020 mice spontaneously develop a new strain of TSE (53). The resulting disease may confound the assessment of TSE transmission to prion-inoculated tg1020 mice. On the other hand, several traits allowed for unequivocal differentiation between transmitted and spontaneous prion disease. First, immunoblots showed the canonical “shift” in electrophoretic mobility in PrPSc recovered from TSE-infected tg1020 mice after PK digestion. This shift has never been detected in spontaneously sick tg1020 mice. Second, inoculated mice showed widespread deposition of PrPSc in the brain, which extended to regions, such as the thalamus, in which aggregates have never been observed in spontaneous disease. Third, the staining profiles of specific LCP dyes and their fluorescence emission spectra differed vastly between inoculated and spontaneously sick tg1020 mice. For example, PTAA failed to stain any brain sections of RL-RML2 and RL hamster strains in tg1020 mice, whereas it consistently labeled spontaneously appearing prion aggregates. Taken together, these features support that the instances of disease reported in this study represent bona fide transmission of TSE rather than spontaneous disease typical of noninoculated tg1020 mice.

tga20 mice express 2-fold more PrPC than the tg1020 mice and would therefore have been expected to develop prion disease after a shorter ip if there was no transmission barrier induced by the S170N and N174T substitutions. However, the tga20 mice only developed prion disease with a shorter ip after inoculation with RML prions and actually had a longer ip after inoculation with CWD prions. With RML infection, the tg1020 mice showed clear evidence of a transmission barrier, in that the ip exceeded that of lower expressing WT mice and shortened by 50% upon second passage. Together, the data clearly support that the differences in prion susceptibility are due to the S170N and N174T substitutions and not due to the differences in PrPC expression.

Consistency of in vivo and in vitro studies of species barriers.

Two decades of published studies indicate that the penetrance of cross-species transmission is affected by the sequence similarity between the host PrPC and the incoming PrPSc (61). Even single–amino acid polymorphisms can radically alter the transmissibility profiles of individual prion strains (6269). Scrapie infection of cells expressing variant sequences of PrPC has also revealed the striking effects of mutations on the efficiency of conversion of PrPC to PrPSc (70).

Hamster prions were successfully transmitted only to tg1020 mice and not to tga20 mice. The hamster PrP sequence is homologous to RL-PrP at position 170 and to WT-PrP at position 174, suggesting that homology at 170 was critical for transmission. Studies of prion transmission in bank voles and PMCA experiments with CWD in a panel of mammalian species also implicate residue 170 as a key position for influencing species barriers (37, 71). These results can be rationalized by classifying TSE hosts into 2 groups: 170S animals that include cattle, sheep, and mice and 170N animals that include elk, deer, hamsters, and RL mice.

Here, we show that susceptibility to a number of prion strains seemed to be driven by homology at position 170, although further experiments with single mutants would be necessary to fully clarify the relative contributions of residues at positions 170 and 174. tga20 mice could readily convert other 170S prions, such as cattle BSE and classical sheep scrapie, but not the 170N prions, such as hamster scrapie. While the overexpressing tga20 mice could convert 170N mule deer CWD prions after a long ip (59), WT mice are resistant to CWD (57, 58). Conversely, tg1020 mice could convert 170N hamster scrapie and mule deer CWD but completely resisted infection with 170S sheep scrapie and BSE (Table (Table3).3). While tg1020 mice may have developed spontaneous infectivity, which would have been detected on further passages, this possibility would not have interfered with the above interpretation.

The above results prompted us to reinterpret published prion transmission experiments and epidemiologic studies in the context of the 170S/170N transmission barrier. In accordance with our predictions, prions are readily transmitted within 170S mammals: sheep scrapie prions infect cattle (7274) and mice (75, 76), and cattle BSE prions readily infect sheep (7779) and mice (14, 80). BSE (170S) has also been transmitted to other 170S species, including greater kudu, nyala, eland, scimitar-horned oryx, bison, rhesus macaque, domestic cat, and mink (13, 16, 81, 82). Conversely, prions generated in 170S animals are poorly transmissible to 170N recipients and vice versa. Transgenic mice overexpressing bovine or ovine PrP completely resisted infection to 9 different CWD isolates (58), and WT mice do not develop clinical prion disease after infection with elk CWD or hamster 263K scrapie (57, 58, 60). Furthermore, cattle and sheep are poorly infectible with mule deer CWD, since few animals develop disease after prolonged ips of 6 years, and only after intracerebral inoculation (83, 84). Among 170N animals, prions are also transmissible, as elk CWD is infectious to hamsters (85), albeit not very efficiently. Collectively, most historical data from studies on species barriers support the model that similarity at the loop region, and particularly the 170S/N switch, impacts transmission barriers in a broad variety of species. As a possible exception to these observations, cattle may be susceptible to CWD from white-tailed deer (86). The latter finding suggests that specific prion strains can overrule the codon 170 homology requirement.

Does the β22 loop direct prion strain conformation?

What are the structural consequences of the substitutions at residues 170 and 174, and how might they explain the important role of these substitutions in interspecies prion transmission? Crystallographic investigations of PrP peptides revealed that adjacent β22 loops can engage in a “dry steric zipper” interface, which was proposed to represent the elemental backbone of many amyloids. Peptide crystal structures encompassing the β22 loops bearing the 170S/174N and 170N/174T substitutions were arranged in a P1 or a P21 crystal space group, respectively (87). These observations suggest striking differences in the β-sheet alignment of PrPSc aggregates between prion-infected 170S and 170N animals and may provide a plausible starting point for clarifying the structural basis of prion species barriers that are highly relevant to public health, including the potential transmissibility of bovine and cervid prions to humans.


Prion inoculations.

tga20 or tg1020 (RL) transgenic mice, which overexpressed murine PrP (52, 53), were intracerebrally inoculated in the left parietal cortex with 30 μl of brain homogenate. This was either a 5%–10% brain homogenate from a terminally sick, naturally CWD-infected mule deer (provided by M. Miller, Colorado Division of Wildlife, Fort Collins, Colorado, USA), an uninfected control deer (reported in ref. 59), a 5% brain homogenate from a terminal, naturally scrapie-infected Suffolk sheep (n = 4 mice) (provided by T. Spraker, Colorado State University, Fort Collins, Colorado, USA), or a 5% brain homogenate from a naturally BSE-infected cow (n = 4 mice) (provided by A. Zurbriggen, University of Bern, Bern, Switzerland). Mice were monitored every second day, and TSE was diagnosed according to clinical criteria, including ataxia, kyphosis, and hind leg paresis. Mice were sacrificed at the onset of terminal disease. Mice were maintained under specific pathogen–free conditions. All of the present studies were reviewed and approved by the animal care and use committee (Kantonales Veterinäramt Zürich) in the Zurich Cantonal Veterinary Office, Switzerland.

Western blots.

The 10% brain or spleen homogenates were prepared in PBS, using a Precellys 24 Tissue Homogenizer. Extracts of 50–90 μg protein were diluted with a Tris-based buffer (10 mM Tris, 10 mM EDTA, 100 mM NaCl, 0.5% NP40, and 0.5% DOC) and digested with 100 μg/ml PK for 30 minutes at 37°C. A SDS-based buffer was then added, and the samples were heated to 95°C for 5 minutes, prior to electrophoresis through a 12% Bis-Tris precast gel (Invitrogen), followed by transfer to a nitrocellulose membrane by wet blotting. Proteins were detected with anti-PrP POM1 antibody (epitope in the globular domain, amino acids 121–231) (88). For secondary detection, we used an HRP-conjugated anti-mouse IgG antibody (Zymed, Invitrogen). Signals were visualized with the ECL detection kit (Pierce). Sodium phosphotungstic acid (NaPTA) precipitation was used when noted to enrich for PrPSc, prior to Western blotting, using published methods (89).


Histoblots were performed as reported in Taraboulos et al. (90), using up to 100 μg/ml of PK for the digestion of PrPC. Histoblots were developed using the anti-PrP POM1 antibody (88).

PTAA staining of frozen tissue sections.

Frozen sections from mouse brain were dried for 1 hour and fixed in 100% and 70% ethanol for 10 minutes each. After washing with deionized water, sections were equilibrated in 100 mM sodium carbonate at pH 10.2 for 30 minutes. The PTAA was diluted in the sodium carbonate buffer (1 μg per 100 μl buffer) and added to the sections. The sections were incubated with PTAA for 30 minutes at room temperature and washed with sodium carbonate buffer. The spectra in the tissue were recorded with a Zeiss Axioplan 2 microscope, fitted with a Spectraview 4.0 (Applied Spectral Imaging) and a Spectra-Cube (interferometrical optical head SD 300) module with cooled CCD camera, through a 470 nm/40 nm (LP 515) bandpass filter (Zeiss) in steps of 10 nm. The data were processed with SpectraView 3.0 EXPO. Spectra were collected from 10 individual spots within 3–4 plaques, from a minimum of 3 different mice of each prion strain.

PTAA staining of formalin-fixed tissue sections.

Paraffin-embedded, formalin-fixed, and formic-acid treated brain sections were deparaffinized and treated with PK (10 μg/ml in PBS) for 10 minutes prior to staining. PTAA staining was performed as described above.

Histopathology and immunohistochemical stains.

Two-μm-thick sections were cut onto positively charged silanized glass slides and stained with H&E or immunostained using antibodies for PrP (SAF84), for astrocytes (GFAP), or microglia (Iba1). For PrP staining, sections were deparaffinized, incubated for 6 minutes in 98% formic acid, and then washed in distilled water for 5 minutes. Sections were heated to 100°C in a pressure cooker in citrate buffer (pH 6.0), cooled for 3 minutes, and washed in distilled water for 5 minutes. Immunohistochemical stains were performed on an automated Nexus staining apparatus (Ventana Medical Systems), using an iVIEW DAB Detection Kit (Ventana Medical Systems). After incubation with protease 1 (Ventana Medical Systems) for 16 minutes, sections were incubated with anti-PrP SAF-84 (SPI-bio; 1:200) for 32 minutes. Sections were counterstained with hematoxylin. GFAP immunohistochemistry (1:1,000 for 24 minutes; DAKO) for astrocytes and Iba1 immunohistochemistry (1:2,500 for 32 minutes; Wako Chemicals) for microglia were similarly performed, but with antigen retrieval, by heating to 100°C in EDTA buffer (pH 8.0).

Serial automated PMCA procedure.

The whole process of in vitro prion replication, including the PrPSc detection of amplified samples, was performed following the basic conditions described previously (9193). The optimization of the technique was performed empirically, taking into account all modifiable parameters. Our optimal results were obtained using the following settings: 60 μl of sample, 70% of power of sonication, 30 minutes of incubation time, 20 seconds of constant sonication, 180 ml of water over the horn plate sonicator, and 37°C–38°C in the water of sonication.


Continuous data are presented as mean ± SD. The ips, from inoculation to terminal prion disease, in the tga20 and tg1020 mice were compared using Student’s unpaired t test. Two-tailed P values of less than 0.05 were considered significant. Statistical analyses were performed using GraphPad Prism.

Supplementary Material

Supplemental data:


We thank our histopathology and animal care staff for technical support. This study was supported by the European Union (TSEUR to A. Aguzzi and UPMAN to K. Wüthrich), the Swiss National Science Foundation, the National Competence Centers for Research on Neural Plasticity and Repair (to A. Aguzzi) and on Structural Biology (to K. Wüthrich), NIH grants K08-AI01802 and 5R21NS055116 (to C.J. Sigurdson), the Foundation for Research at the University of Zürich (to C.J. Sigurdson), the US National Prion Research Program (to C.J. Sigurdson and A. Aguzzi), the Knut and Alice Wallenberg Foundation (to K.P.R. Nilsson), and the ETH Zürich (to K. Wüthrich). K. Wüthrich is the Cecil H. and Ida M. Green Professor of Structural Biology at The Scripps Research Institute.


Conflict of interest: Adriano Aguzzi receives funding from the Novartis Foundation.

Citation for this article: J Clin Invest. 2010;120(7):2590–2599. doi:10.1172/JCI42051.

K. Peter R. Nilsson’s present address is: Department of Chemistry, IFM, Linköping University, Linköping, Sweden.

Simone Hornemann’s present address is: UniversitätsSpital Zürich, Institute of Neuropathology, Zürich, Switzerland.


1. Aguzzi A. Understanding the diversity of prions. Nat Cell Biol. 2004;6(4):290–292. doi: 10.1038/ncb0404-290. [PubMed] [Cross Ref]
2. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science. 1982;216(4542):136–144. doi: 10.1126/science.6801762. [PubMed] [Cross Ref]
3. Prusiner SB. Molecular biology of prion diseases. Science. 1991;252(5012):1515–1522. doi: 10.1126/science.1675487. [PubMed] [Cross Ref]
4. Collinge J, Clarke AR. A general model of prion strains and their pathogenicity. Science. 2007;318(5852):930–936. doi: 10.1126/science.1138718. [PubMed] [Cross Ref]
5. Fraser H, Dickinson AG. The sequential development of the brain lesion of scrapie in three strains of mice. J Comp Pathol. 1968;78(3):301–311. doi: 10.1016/0021-9975(68)90006-6. [PubMed] [Cross Ref]
6. Fraser H, Dickinson AG. Scrapie in mice. Agent-strain differences in the distribution and intensity of grey matter vacuolation. J Comp Pathol. 1973;83(1):29–40. doi: 10.1016/0021-9975(73)90024-8. [PubMed] [Cross Ref]
7. Bruce ME, McBride PA, Farquhar CF. Precise targeting of the pathology of the sialoglycoprotein, PrP, and vacuolar degeneration in mouse scrapie. Neurosci Lett. 1989;102(1):1–6. doi: 10.1016/0304-3940(89)90298-X. [PubMed] [Cross Ref]
8. Bessen RA, Marsh RF. Biochemical and physical properties of the prion protein from two strains of the transmissible mink encephalopathy agent. J Virol. 1992;66(4):2096–2101. [PMC free article] [PubMed]
9. Hill AF, et al. Distinct glycoform ratios of protease resistant prion protein associated with PRNP point mutations. . Brain. 2006;129(pt 3):676–685. doi: 10.1093/brain/awl013. [PubMed] [Cross Ref]
10. Safar J, et al. Eight prion strains have PrPSc molecules with different conformations. . Nature Medicine. 1998;4(10):1157–1165. doi: 10.1038/2654. [PubMed] [Cross Ref]
11. Peretz D, et al. A change in the conformation of prions accompanies the emergence of a new prion strain. Neuron. 2002;34(6):921–932. doi: 10.1016/S0896-6273(02)00726-2. [PubMed] [Cross Ref]
12. Will RG, et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet. 1996;347(9006):921–925. doi: 10.1016/S0140-6736(96)91412-9. [PubMed] [Cross Ref]
13. Collinge J, Sidle KC, Meads J, Ironside J, Hill AF. Molecular analysis of prion strain variation and the aetiology of ‘new variant’ CJD. Nature. 1996;383(6602):685–690. doi: 10.1038/383685a0. [PubMed] [Cross Ref]
14. Bruce ME, et al. Transmissions to mice indicate that ‘new variant’ CJD is caused by the BSE agent. Nature. 1997;389(6650):498–501. doi: 10.1038/39057. [PubMed] [Cross Ref]
15. Seitz R, et al. Impact of vCJD on blood supply. Biologicals. 2007;35(2):79–97. doi: 10.1016/j.biologicals.2007.01.002. [PubMed] [Cross Ref]
16. Kirkwood JK, Cunningham AA. Epidemiological observations on spongiform encephalopathies in captive wild animals in the British Isles. Vet Rec. 1994;135(13):296–303. [PubMed]
17. Ryder SJ, Wells GA, Bradshaw JM, Pearson GR. Inconsistent detection of PrP in extraneural tissues of cats with feline spongiform encephalopathy. Vet Rec. 2001;148(14):437–441. [PubMed]
18. Kirkwood JK, Cunningham AA, Wells GA, Wilesmith JW, Barnett JE. Spongiform encephalopathy in a herd of greater kudu (Tragelaphus strepsiceros): epidemiological observations. Vet Rec. 1993;133(15):360–364. [PubMed]
19. Sigurdson CJ, Miller MW. Other animal prion diseases. Br Med Bull. 2003;66:199–212. doi: 10.1093/bmb/66.1.199. [PubMed] [Cross Ref]
20. Pattison IH, Jones KM. Modification of a strain of mouse-adapted scrapie by passage through rats. Res Vet Sci. 1968;9(5):408–410. [PubMed]
21. Benestad SL, Sarradin P, Thu B, Schonheit J, Tranulis MA, Bratberg B. Cases of scrapie with unusual features in Norway and designation of a new type, Nor98. Vet Rec. 2003;153(7):202–208. [PubMed]
22. Sofianidis G, Psychas V, Billinis C, Spyrou V, Argyroudis S, Vlemmas I. Atypical PrPSc distribution in goats naturally affected with scrapie. . J Comp Pathol. 2008;138(2–3):90–101. [PubMed]
23. Biacabe AG, Laplanche JL, Ryder S, Baron T. Distinct molecular phenotypes in bovine prion diseases. EMBO Rep. 2004;5(1):110–115. doi: 10.1038/sj.embor.7400054. [PubMed] [Cross Ref]
24. Casalone C, et al. Identification of a second bovine amyloidotic spongiform encephalopathy: molecular similarities with sporadic Creutzfeldt-Jakob disease. Proc Natl Acad Sci U S A. 2004;101(9):3065–3070. doi: 10.1073/pnas.0305777101. [PubMed] [Cross Ref]
25. Telling GC, et al. Transmission of Creutzfeldt-Jakob disease from humans to transgenic mice expressing chimeric human-mouse prion protein. Proc Natl Acad Sci U S A. 1994;91(21):9936–9940. doi: 10.1073/pnas.91.21.9936. [PubMed] [Cross Ref]
26. Telling GC, et al. Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein. Cell. 1995;83(1):79–90. doi: 10.1016/0092-8674(95)90236-8. [PubMed] [Cross Ref]
27. Priola SA, Chesebro B. A single hamster PrP amino acid blocks conversion to protease-resistant PrP in scrapie-infected mouse neuroblastoma cells. J Virol. 1995;69(12):7754–7758. [PMC free article] [PubMed]
28. Horiuchi M, Priola SA, Chabry J, Caughey B. Interactions between heterologous forms of prion protein: binding, inhibition of conversion, and species barriers. Proc Natl Acad Sci U S A. 2000;97(11):5836–5841. doi: 10.1073/pnas.110523897. [PubMed] [Cross Ref]
29. Kocisko DA, Priola SA, Raymond GJ, Chesebro B, Lansbury PT, Jr, Caughey B. Species specificity in the cell-free conversion of prion protein to protease-resistant forms: a model for the scrapie species barrier. Proc Natl Acad Sci U S A. 1995;92(9):3923–3927. doi: 10.1073/pnas.92.9.3923. [PubMed] [Cross Ref]
30. Scott M, et al. Transgenic mice expressing hamster prion protein produce species-specific scrapie infectivity and amyloid plaques. Cell. 1989;59(5):847–857. doi: 10.1016/0092-8674(89)90608-9. [PubMed] [Cross Ref]
31. Prusiner SB, et al. Transgenetic studies implicate interactions between homologous PrP isoforms in scrapie prion replication. Cell. 1990;63(4):673–686. doi: 10.1016/0092-8674(90)90134-Z. [PubMed] [Cross Ref]
32. Race R, Meade-White K, Raines A, Raymond GJ, Caughey B, Chesebro B. Subclinical scrapie infection in a resistant species: persistence, replication, and adaptation of infectivity during four passages. J Infect Dis. 2002;186(suppl 2):S166–S170. doi: 10.1086/344267. [PubMed] [Cross Ref]
33. Barron RM, et al. Changing a single amino acid in the N-terminus of murine PrP alters TSE incubation time across three species barriers. EMBO J. 2001;20(18):5070–5078. doi: 10.1093/emboj/20.18.5070. [PubMed] [Cross Ref]
34. Barron RM, Manson JC. A gene-targeted mouse model of P102L Gerstmann-Sträussler-Scheinker syndrome. Clin Lab Med. 2003;23(1):161–173. doi: 10.1016/S0272-2712(02)00067-7. [PubMed] [Cross Ref]
35. Collinge J, Beck J, Campbell T, Estibeiro K, Will RG. Prion protein gene analysis in new variant cases of Creutzfeldt-Jakob disease. Lancet. 1996;348(9019):56. [PubMed]
36. Nonno R, et al. Efficient transmission and characterization of Creutzfeldt-Jakob disease strains in bank voles. PLoS Pathog. 2006;2(2):e12. doi: 10.1371/journal.ppat.0020012. [PMC free article] [PubMed] [Cross Ref]
37. Piening N, et al. Conversion efficiency of bank vole prion protein in vitro is determined by residues 155 and 170, but does not correlate with the high susceptibility of bank voles to sheep scrapie in vivo. J Biol Chem. 2006;281(14):9373–9384. doi: 10.1074/jbc.M512239200. [PubMed] [Cross Ref]
38. Wopfner F, et al. Analysis of 27 mammalian and 9 avian PrPs reveals high conservation of flexible regions of the prion protein. J Mol Biol. 1999;289(5):1163–1178. doi: 10.1006/jmbi.1999.2831. [PubMed] [Cross Ref]
39. Billeter M, Riek R, Wider G, Hornemann S, Glockshuber R, Wüthrich K. Prion protein NMR structure and species barrier for prion diseases. Proc Natl Acad Sci U S A. 1997;94(14):7281–7285. doi: 10.1073/pnas.94.14.7281. [PubMed] [Cross Ref]
40. Riek R, Hornemann S, Wider G, Billeter M, Glockshuber R, Wüthrich K. NMR Structure of the Mouse Prion Protein Domain Prp(121–231). Nature. 1996;382(6587):180–182. doi: 10.1038/382180a0. [PubMed] [Cross Ref]
41. Gorfe AA, Caflisch A. Ser170 controls the conformational multiplicity of the loop 166-175 in prion proteins: implication for conversion and species barrier. FASEB J. 2007;21(12):3279–3287. doi: 10.1096/fj.07-8292com. [PubMed] [Cross Ref]
42. Riek R, Hornemann S, Wider G, Glockshuber R, Wüthrich K. NMR characterization of the full-length recombinant murine prion protein, mPrP(23–231). FEBS Lett. 1997;413(2):282–288. doi: 10.1016/S0014-5793(97)00920-4. [PubMed] [Cross Ref]
43. Hornemann S, Schorn C, Wüthrich K. NMR structure of the bovine prion protein isolated from healthy calf brains. EMBO Rep. 2004;5(12):1159–1164. doi: 10.1038/sj.embor.7400297. [PubMed] [Cross Ref]
44. Liu H, et al. Solution structure of Syrian hamster prion protein rPrP(90–231). Biochemistry. 1999;38(17):5362–5377. doi: 10.1021/bi982878x. [PubMed] [Cross Ref]
45. Lopez Garcia F, Zahn R, Riek R, Wüthrich K. NMR structure of the bovine prion protein. Proc Natl Acad Sci U S A. 2000;97(15):8334–8339. doi: 10.1073/pnas.97.15.8334. [PubMed] [Cross Ref]
46. Lysek DA, et al. Prion protein NMR structures of cats, dogs, pigs, and sheep. Proc Natl Acad Sci U S A. 2005;102(3):640–645. doi: 10.1073/pnas.0408937102. [PubMed] [Cross Ref]
47. Zahn R, et al. NMR solution structure of the human prion protein. Proc Natl Acad Sci U S A. 2000;97(1):145–150. doi: 10.1073/pnas.97.1.145. [PubMed] [Cross Ref]
48. Schätzl HM, Da Costa M, Taylor L, Cohen FE, Prusiner SB. Prion protein gene variation among primates. J Mol Biol. 1995;245(4):362–374. doi: 10.1006/jmbi.1994.0030. [PubMed] [Cross Ref]
49. Christen B, Hornemann S, Damberger FF, Wüthrich K. Prion protein NMR structure from tammar wallaby (Macropus eugenii) shows that the beta2-alpha2 loop is modulated by long-range sequence effects. J Mol Biol. 2009;389(5):833–845. doi: 10.1016/j.jmb.2009.04.040. [PubMed] [Cross Ref]
50. Christen B, Perez DR, Hornemann S, Wüthrich K. NMR structure of the bank vole prion protein at 20 degrees C contains a structured loop of residues 165-171. J Mol Biol. 2008;383(2):306–312. doi: 10.1016/j.jmb.2008.08.045. [PubMed] [Cross Ref]
51. Gossert AD, Bonjour S, Lysek DA, Fiorito F, Wüthrich K. Prion protein NMR structures of elk and of mouse/elk hybrids. Proc Natl Acad Sci U S A. 2005;102(3):646–650. doi: 10.1073/pnas.0409008102. [PubMed] [Cross Ref]
52. Fischer M, et al. Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie. EMBO J. 1996;15(6):1255–1264. [PubMed]
53. Sigurdson CJ, et al. De novo generation of a transmissible spongiform encephalopathy by mouse transgenesis. Proc Natl Acad Sci U S A. 2009;106(1):304–309. doi: 10.1073/pnas.0810680105. [PubMed] [Cross Ref]
54. Ding L, Jonforsen M, Roman LS, Andersson MR, Inganas O. Photovoltaic cells with a conjugated polyelectrolyte. Synth Met. 2000;110(2):133–140. doi: 10.1016/S0379-6779(99)00284-2. [Cross Ref]
55. Nilsson KPR, et al. Imaging distinct conformational states of amyloid-beta fibrils in Alzheimer’s disease using novel luminescent probes. ACS Chem Biol. 2007;2(8):553–560. doi: 10.1021/cb700116u. [PubMed] [Cross Ref]
56. Sigurdson CJ, et al. Prion strain discrimination using luminescent conjugated polymers. Nat Methods. 2007;4(12):1023–1030. doi: 10.1038/nmeth1131. [PubMed] [Cross Ref]
57. Browning SR, et al. Transmission of prions from mule deer and elk with chronic wasting disease to transgenic mice expressing cervid PrP. J Virol. 2004;78(23):13345–13350. doi: 10.1128/JVI.78.23.13345-13350.2004. [PMC free article] [PubMed] [Cross Ref]
58. Tamguney G, et al. Transmission of elk and deer prions to transgenic mice. J Virol. 2006;80(18):9104–9114. doi: 10.1128/JVI.00098-06. [PMC free article] [PubMed] [Cross Ref]
59. Sigurdson CJ, et al. Strain fidelity of chronic wasting disease upon murine adaptation. J Virol. 2006;80(24):12303–12311. doi: 10.1128/JVI.01120-06. [PMC free article] [PubMed] [Cross Ref]
60. Kimberlin RH, Walker CA. Evidence that the transmission of one source of scrapie agent to hamsters involves separation of agent strains from a mixture. J Gen Virol. 1978;39(3):487–496. doi: 10.1099/0022-1317-39-3-487. [PubMed] [Cross Ref]
61. Scott M, et al. Propagation of prions with artificial properties in transgenic mice expressing chimeric PrP genes. Cell. 1993;73(5):979–988. doi: 10.1016/0092-8674(93)90275-U. [PubMed] [Cross Ref]
62. Moore RC, et al. Mice with gene targetted prion protein alterations show that Prnp, Sinc and Prni are congruent. Nat Genet. 1998;18(2):118–125. doi: 10.1038/ng0298-118. [PubMed] [Cross Ref]
63. Wadsworth JD, Collinge J. Update on human prion disease. Biochim Biophys Acta. 2007;1772(6):598–609. [PubMed]
64. O’Rourke KI, et al. PrP genotypes of captive and free-ranging Rocky Mountain elk (Cervus elaphus nelsoni) with chronic wasting disease. J Gen Virol. 1999;80(pt 10):2765–2769. [PubMed]
65. Jewell JE, Conner MM, Wolfe LL, Miller MW, Williams ES. Low frequency of PrP genotype 225SF among free-ranging mule deer (Odocoileus hemionus) with chronic wasting disease. J Gen Virol. 2005;86(pt 8):2127–2134. doi: 10.1099/vir.0.81077-0. [PubMed] [Cross Ref]
66. Johnson C, Johnson J, Vanderloo JP, Keane D, Aiken JM, McKenzie D. Prion protein polymorphisms in white-tailed deer influence susceptibility to chronic wasting disease. J Gen Virol. 2006;87(pt 7):2109–2114. doi: 10.1099/vir.0.81615-0. [PubMed] [Cross Ref]
67. Meade-White K, et al. Resistance to chronic wasting disease in transgenic mice expressing a naturally occurring allelic variant of deer prion protein. J Virol. 2007;81(9):4533–4539. doi: 10.1128/JVI.02762-06. [PMC free article] [PubMed] [Cross Ref]
68. Jones EM, Surewicz WK. Fibril conformation as the basis of species- and strain-dependent seeding specificity of mammalian prion amyloids. Cell. 2005;121(1):63–72. doi: 10.1016/j.cell.2005.01.034. [PubMed] [Cross Ref]
69. Vanik DL, Surewicz KA, Surewicz WK. Molecular basis of barriers for interspecies transmissibility of mammalian prions. Mol Cell. 2004;14(1):139–145. doi: 10.1016/S1097-2765(04)00155-8. [PubMed] [Cross Ref]
70. Vorberg I, Groschup MH, Pfaff E, Priola SA. Multiple amino acid residues within the rabbit prion protein inhibit formation of its abnormal isoform. J Virol. 2003;77(3):2003–2009. doi: 10.1128/JVI.77.3.2003-2009.2003. [PMC free article] [PubMed] [Cross Ref]
71. Kurt TD, Telling GT, Zabel MD, Hoover EA. Trans-species amplification of PrPCWD and correlation with rigid loop 170N. Virology. 2009;387(1):235–243. doi: 10.1016/j.virol.2009.02.025. [PubMed] [Cross Ref]
72. Cutlip RC, et al. Intracerebral transmission of scrapie to cattle. J Infect Dis. 1994;169(4):814–820. [PubMed]
73. Cutlip RC, Miller JM, Lehmkuhl HD. Second passage of a US scrapie agent in cattle. J Comp Pathol. 1997;117(3):271–275. doi: 10.1016/S0021-9975(97)80022-9. [PubMed] [Cross Ref]
74. Robinson MM, et al. Experimental infection of cattle with the agents of transmissible mink encephalopathy and scrapie. J Comp Pathol. 1995;113(3):241–251. doi: 10.1016/S0021-9975(05)80039-8. [PubMed] [Cross Ref]
75. Fraser H, Bruce ME, Chree A, McConnell I, Wells GA. Transmission of bovine spongiform encephalopathy and scrapie to mice. J Gen Virol. 1992;73(pt 8):1891–1897. doi: 10.1099/0022-1317-73-8-1891. [PubMed] [Cross Ref]
76. Baron T, et al. Molecular analysis of the protease-resistant prion protein in scrapie and bovine spongiform encephalopathy transmitted to ovine transgenic and wild-type mice. J Virol. 2004;78(12):6243–6251. doi: 10.1128/JVI.78.12.6243-6251.2004. [PMC free article] [PubMed] [Cross Ref]
77. Jeffrey M, et al. Oral inoculation of sheep with the agent of bovine spongiform encephalopathy (BSE). 1. Onset and distribution of disease-specific PrP accumulation in brain and viscera. J Comp Pathol. 2001;124(4):280–289. doi: 10.1053/jcpa.2001.0465. [PubMed] [Cross Ref]
78. Gonzalez L, et al. Phenotype of disease-associated PrP accumulation in the brain of bovine spongiform encephalopathy experimentally infected sheep. J Gen Virol. 2005;86(pt 3):827–838. doi: 10.1099/vir.0.80299-0. [PubMed] [Cross Ref]
79. Martin S, Gonzalez L, Chong A, Houston FE, Hunter N, Jeffrey M. Immunohistochemical characteristics of disease-associated PrP are not altered by host genotype or route of inoculation following infection of sheep with bovine spongiform encephalopathy. J Gen Virol. 2005;86(pt 3):839–848. doi: 10.1099/vir.0.80364-0. [PubMed] [Cross Ref]
80. Green R, Horrocks C, Wilkinson A, Hawkins SA, Ryder SJ. Primary isolation of the bovine spongiform encephalopathy agent in mice: agent definition based on a review of 150 transmissions. J Comp Pathol. 2005;132(2–3):117–131. doi: 10.1016/j.jcpa.2004.08.002. [PubMed] [Cross Ref]
81. Robinson MM, et al. Experimental infection of mink with bovine spongiform encephalopathy. J Gen Virol. 1994;75(pt 9):2151–2155. doi: 10.1099/0022-1317-75-9-2151. [PubMed] [Cross Ref]
82. Wyatt JM, Pearson GR, Smerdon TN, Gruffydd Jones TJ, Wells GA, Wilesmith JW. Naturally occurring scrapie-like spongiform encephalopathy in five domestic cats. Vet Rec. 1991;129(11):233–236. [PubMed]
83. Hamir AN, Kunkle RA, Cutlip RC, Miller JM, Williams ES, Richt JA. Transmission of chronic wasting disease of mule deer to Suffolk sheep following intracerebral inoculation. J Vet Diagn Invest. 2006;18(6):558–565. [PubMed]
84. Hamir AN, et al. Experimental transmission of chronic wasting disease agent from mule deer to cattle by the intracerebral route. J Vet Diagn Invest. 2005;17(3):276–281. [PubMed]
85. Raymond GJ, et al. Transmission and adaptation of chronic wasting disease to hamsters and transgenic mice: evidence for strains. J Virol. 2007;81(8):4305–4314. doi: 10.1128/JVI.02474-06. [PMC free article] [PubMed] [Cross Ref]
86. Hamir AN, Miller JM, Kunkle RA, Hall SM, Richt JA. Susceptibility of cattle to first-passage intracerebral inoculation with chronic wasting disease agent from white-tailed deer. Vet Pathol. 2007;44(4):487–493. doi: 10.1354/vp.44-4-487. [PubMed] [Cross Ref]
87. Sawaya MR, et al. Atomic structures of amyloid cross-beta spines reveal varied steric zippers. Nature. 2007;447(7143):453–457. doi: 10.1038/nature05695. [PubMed] [Cross Ref]
88. Polymenidou M, Stoeck K, Glatzel M, Vey M, Bellon A, Aguzzi A. Coexistence of multiple PrPSc types in individuals with Creutzfeldt-Jakob disease. Lancet Neurol. 2005;4(12):805–814. doi: 10.1016/S1474-4422(05)70225-8. [PubMed] [Cross Ref]
89. Wadsworth JDF, et al. Tissue distribution of protease resistant prion protein in variant CJD using a highly sensitive immuno-blotting assay. Lancet. 2001;358(9277):171–180. doi: 10.1016/S0140-6736(01)05403-4. [PubMed] [Cross Ref]
90. Taraboulos A, Jendroska K, Serban D, Yang SL, DeArmond SJ, Prusiner SB. Regional mapping of prion proteins in brain. Proc Natl Acad Sci U S A. 1992;89(16):7620–7624. doi: 10.1073/pnas.89.16.7620. [PubMed] [Cross Ref]
91. Castilla J, Gonzalez-Romero D, Saa P, Morales R, De Castro J, Soto C. Crossing the species barrier by PrP(Sc) replication in vitro generates unique infectious prions. Cell. 2008;134(5):757–768. doi: 10.1016/j.cell.2008.07.030. [PMC free article] [PubMed] [Cross Ref]
92. Castilla J, Saa P, Hetz C, Soto C. In vitro generation of infectious scrapie prions. Cell. 2005;121(2):195–206. doi: 10.1016/j.cell.2005.02.011. [PubMed] [Cross Ref]
93. Castilla J, Saa P, Morales R, Abid K, Maundrell K, Soto C. Protein misfolding cyclic amplification for diagnosis and prion propagation studies. Methods Enzymol. 2006;412:3–21. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation